JP2018502060A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502060A5 JP2018502060A5 JP2017526534A JP2017526534A JP2018502060A5 JP 2018502060 A5 JP2018502060 A5 JP 2018502060A5 JP 2017526534 A JP2017526534 A JP 2017526534A JP 2017526534 A JP2017526534 A JP 2017526534A JP 2018502060 A5 JP2018502060 A5 JP 2018502060A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- chain
- pharmaceutical composition
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 27
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 4
- 241000282567 Macaca fascicularis Species 0.000 claims description 4
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 4
- 206010057249 Phagocytosis Diseases 0.000 claims description 3
- 101150036449 SIRPA gene Proteins 0.000 claims description 3
- 230000035931 haemagglutination Effects 0.000 claims description 3
- 102000044459 human CD47 Human genes 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000008782 phagocytosis Effects 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 6
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 6
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 6
- 239000004172 quinoline yellow Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081134P | 2014-11-18 | 2014-11-18 | |
| US62/081,134 | 2014-11-18 | ||
| PCT/US2015/061014 WO2016081423A1 (en) | 2014-11-18 | 2015-11-17 | Cd47 antibodies, methods, and uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502060A JP2018502060A (ja) | 2018-01-25 |
| JP2018502060A5 true JP2018502060A5 (OSRAM) | 2020-01-30 |
| JP6857603B2 JP6857603B2 (ja) | 2021-04-14 |
Family
ID=54705894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526534A Expired - Fee Related JP6857603B2 (ja) | 2014-11-18 | 2015-11-17 | 抗ｃｄ１４７抗体、方法及び使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10864268B2 (OSRAM) |
| EP (1) | EP3221358B1 (OSRAM) |
| JP (1) | JP6857603B2 (OSRAM) |
| KR (1) | KR20170081699A (OSRAM) |
| CN (1) | CN107406503B (OSRAM) |
| AU (1) | AU2015350190B2 (OSRAM) |
| BR (1) | BR112017010303A2 (OSRAM) |
| CA (1) | CA2967379A1 (OSRAM) |
| EA (1) | EA201791093A1 (OSRAM) |
| IL (1) | IL252198A0 (OSRAM) |
| MX (1) | MX2017006485A (OSRAM) |
| PH (1) | PH12017500915A1 (OSRAM) |
| SG (1) | SG11201704058TA (OSRAM) |
| WO (1) | WO2016081423A1 (OSRAM) |
| ZA (1) | ZA201704117B (OSRAM) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX374853B (es) | 2015-02-19 | 2025-03-06 | Compugen Ltd | Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso. |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US10259859B2 (en) | 2015-08-07 | 2019-04-16 | ALX Oncology Inc. | Constructs having a SIRP-α domain or variant thereof |
| US11649284B2 (en) * | 2016-04-18 | 2023-05-16 | Baylor College Of Medicine | Cancer gene therapy targeting CD47 |
| CN106084052B (zh) | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| US12344669B2 (en) | 2016-06-17 | 2025-07-01 | Changchun Genescience Pharmaceutical Co., Ltd. | Anti-CD47 monoclonal antibody and use thereof |
| AU2017292752B2 (en) | 2016-07-06 | 2023-07-27 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
| WO2018012952A1 (ko) * | 2016-07-15 | 2018-01-18 | 한국과학기술연구원 | 신규 나노케이지 및 그의 용도 |
| EP4124343A1 (en) * | 2016-10-20 | 2023-02-01 | I-Mab Biopharma US Limited | Novel cd47 monoclonal antibodies and uses thereof |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| EP3661965A4 (en) * | 2017-08-02 | 2022-07-13 | Phanes Therapeutics, Inc. | ANTI-CD47 ANTIBODIES AND USES THEREOF |
| US11708418B2 (en) * | 2017-08-10 | 2023-07-25 | Grifols Diagnostic Solutions Inc. | Compositions, methods and/or kits comprising a recombinant human CD38- extracellular domain |
| EP4435008A2 (en) | 2017-08-18 | 2024-09-25 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| US20210188952A1 (en) * | 2017-11-17 | 2021-06-24 | University Of Massachusetts | Humanized 2c7 monoclonal antibody directed against a neisseria gonorrhoeae lipooligosaccharide (los) epitope, for human use |
| US11180552B2 (en) | 2017-12-01 | 2021-11-23 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
| CN110144009B (zh) * | 2018-02-14 | 2020-01-21 | 上海洛启生物医药技术有限公司 | Cd47单域抗体及其用途 |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| WO2019241732A1 (en) | 2018-06-15 | 2019-12-19 | Accurus Biosciences, Inc. | Blocking antibodies against cd47 and methods of use thereof |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| KR102587442B1 (ko) * | 2018-08-31 | 2023-10-11 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 항-cd47 항체 또는 그 적용 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| AU2020229467A1 (en) | 2019-02-26 | 2021-08-12 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-EGFR/c-met antibodies |
| US10858442B2 (en) | 2019-04-18 | 2020-12-08 | Qlsf Biotherapeutics Inc. | Antibodies that target human CD47 |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| PH12021552798A1 (en) | 2019-05-14 | 2022-09-19 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| CN119700933A (zh) | 2019-05-31 | 2025-03-28 | Alx肿瘤生物技术公司 | 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| WO2020247820A1 (en) | 2019-06-07 | 2020-12-10 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| EP4025686A4 (en) | 2019-09-03 | 2023-09-13 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| WO2021078219A1 (en) * | 2019-10-25 | 2021-04-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-cd47 antibodies and uses thereof |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CA3172449A1 (en) | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| CN120040592A (zh) * | 2020-07-31 | 2025-05-27 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
| WO2022098642A1 (en) | 2020-11-03 | 2022-05-12 | Rdiscovery, LLC | Therapies for treatment of cancer and phagocytosis-deficiency related diseases |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| JP2023552375A (ja) | 2020-12-06 | 2023-12-15 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体 |
| WO2022148383A1 (en) * | 2021-01-05 | 2022-07-14 | National Institute Of Biological Sciences, Beijing | A bispecific antibody targeting gpc3 and cd47 |
| JP7699210B2 (ja) * | 2021-01-08 | 2025-06-26 | 北京韓美薬品有限公司 | Ｃｄ４７と特異的に結合する抗体及びその抗原結合フラグメント |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| AU2022237618A1 (en) | 2021-03-17 | 2023-10-12 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024518100A (ja) | 2021-05-11 | 2024-04-24 | マイエロイド・セラピューティクス，インコーポレーテッド | ゲノム組込みのための方法および組成物 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4365197A4 (en) * | 2021-06-30 | 2025-05-14 | Innobation Bio Co., Ltd. | Humanized antibody specific to CD47 and pharmaceutical composition containing it for the prevention or treatment of CD47-mediated disease |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN114371282B (zh) * | 2021-12-30 | 2025-07-11 | 上海药明生物技术有限公司 | 一种评估抗原沉默效应对抗体药效影响的方法及其应用 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| EP4554628A1 (en) | 2022-07-12 | 2025-05-21 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120344257A (zh) | 2022-12-09 | 2025-07-18 | 美国辉瑞有限公司 | Cd47阻断剂和抗cd20/抗cd3双特异性抗体组合疗法 |
| KR20250116736A (ko) | 2022-12-09 | 2025-08-01 | 화이자 인코포레이티드 | Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법 |
| CN118221812A (zh) * | 2022-12-14 | 2024-06-21 | 上海迈石生物技术有限公司 | 一种靶向cd47的单克隆抗体及其应用 |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120584133A (zh) * | 2022-12-29 | 2025-09-02 | 上海复宏汉霖生物技术股份有限公司 | 抗cd47抗体及使用方法 |
| CN120882752A (zh) | 2023-03-13 | 2025-10-31 | 詹森生物科技公司 | 双特异性抗EGFR/c-Met抗体和抗PD-1抗体的组合疗法 |
| KR20250167002A (ko) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Kras 조절 화합물 |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3068506A (en) | 1958-02-19 | 1962-12-18 | Trico Products Corp | Combined windshield cleaner and washer |
| US3068507A (en) | 1959-08-28 | 1962-12-18 | Babcock & Wilcox Ltd | Fluid heater cleaners |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992010190A1 (en) | 1990-12-13 | 1992-06-25 | Smithkline Beecham Corporation | Novel csaids |
| KR100252547B1 (ko) | 1991-09-05 | 2000-09-01 | 프레드 마리얀스키 | 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달 |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| WO1993016043A1 (en) | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| GB9930706D0 (en) * | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| KR100870123B1 (ko) * | 2000-10-20 | 2008-11-25 | 츄가이 세이야꾸 가부시키가이샤 | 저분자화 아고니스트 항체 |
| AU2002210918B2 (en) | 2000-10-20 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Degraded agonist antibody |
| CA2545166A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| JP5027804B2 (ja) * | 2005-05-26 | 2012-09-19 | シアトル ジェネティクス，インコーポレーテッド | ヒト化抗ｃｄ４０抗体およびその使用方法 |
| CN101970730A (zh) | 2007-12-19 | 2011-02-09 | 森托科尔奥索生物科技公司 | 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法 |
| SI2506871T1 (sl) | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| JP6166177B2 (ja) * | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 |
| SMT202000689T1 (it) * | 2012-01-17 | 2021-01-05 | Univ Leland Stanford Junior | Reagenti per sirp-alfa ad alta affinita' |
| SG10201700160RA (en) * | 2012-02-06 | 2017-03-30 | Inhibrx Lp | Cd47 antibodies and methods of use thereof |
| BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| US9873747B2 (en) * | 2013-01-31 | 2018-01-23 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| CN105101997B (zh) * | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | 不减少血小板和不减少血红细胞的cd47抗体及其使用方法 |
-
2015
- 2015-11-17 MX MX2017006485A patent/MX2017006485A/es unknown
- 2015-11-17 CN CN201580073804.7A patent/CN107406503B/zh not_active Expired - Fee Related
- 2015-11-17 SG SG11201704058TA patent/SG11201704058TA/en unknown
- 2015-11-17 US US15/527,551 patent/US10864268B2/en not_active Expired - Fee Related
- 2015-11-17 KR KR1020177016228A patent/KR20170081699A/ko not_active Withdrawn
- 2015-11-17 AU AU2015350190A patent/AU2015350190B2/en not_active Ceased
- 2015-11-17 WO PCT/US2015/061014 patent/WO2016081423A1/en not_active Ceased
- 2015-11-17 EP EP15801630.3A patent/EP3221358B1/en active Active
- 2015-11-17 EA EA201791093A patent/EA201791093A1/ru unknown
- 2015-11-17 JP JP2017526534A patent/JP6857603B2/ja not_active Expired - Fee Related
- 2015-11-17 BR BR112017010303A patent/BR112017010303A2/pt not_active Application Discontinuation
- 2015-11-17 CA CA2967379A patent/CA2967379A1/en not_active Abandoned
-
2017
- 2017-05-10 IL IL252198A patent/IL252198A0/en unknown
- 2017-05-17 PH PH12017500915A patent/PH12017500915A1/en unknown
- 2017-06-15 ZA ZA2017/04117A patent/ZA201704117B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502060A5 (OSRAM) | ||
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| US10781256B2 (en) | Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies | |
| CN110799540B (zh) | 多特异性抗体及其制备和使用方法 | |
| TW201837174A (zh) | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 | |
| JP2020525032A5 (OSRAM) | ||
| JP2016507555A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| JP2011509245A5 (OSRAM) | ||
| JP2014526898A5 (OSRAM) | ||
| CN104105708A (zh) | PDGF受体β结合多肽 | |
| US20220185908A1 (en) | Methods of use of anti-cd19/anti-cd38 common light chain bispecific antibodies | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| CN110305214A (zh) | 新型抗cd47抗体 | |
| WO2021173844A1 (en) | C19 c38 bispecific antibodies | |
| CA3156983A1 (en) | Antibodies against the poliovirus receptor (pvr) and uses thereof | |
| CN118139639A (zh) | 治疗与免疫抑制b细胞相关联的癌症的方法 | |
| CN115151572B (zh) | 针对ror1的抗体及其用途 | |
| JP2025526279A (ja) | 抗ＴＮＦα抗体および組成物 | |
| EP4499702A2 (en) | Anti-adenosine receptor (a2ar) antibodies and the use thereof | |
| US12509527B2 (en) | Anti-CD19/anti-CD38 common light chain bispecific antibodies | |
| EP4626919A1 (en) | Protease cleavable recombinant bispecific antibodies and compositions and uses thereof | |
| CN118871465A (zh) | 针对btla的抗体及其用途 | |
| HK40019010B (zh) | 多特异性抗体及其制备和使用方法 |